Europe In-Vitro Diagnostics (IVD) Market Report by Test Types, Product, Application, Technology, End User, Countries and Companies Analysis 2026-2034

Europe In-Vitro Diagnostics Market Size & Forecast 2026-2034

European IVD (In Vitro Diagnostics) market is projected to witness significant growth owing to an increased need for early detection of diseases, personalized medicines, and advanced technology in diagnostics. The European IVD market is forecast to grow from US$ 26.54 billion in 2025 to US$ 43.75 billion in 2034 at a CAGR of 5.71% during 2026-2034. The growing incidence of chronic diseases, the expanding elderly population, and technological advances in molecular diagnostics and point-of-care diagnostics are also contributing to the growth of the market.

Europe In-Vitro Diagnostics Industry Outlooks

In-Vitro Diagnostics is defined as medical diagnostics done outside the body using bodily fluids such as blood, urine, tissue, or saliva. The purpose of these diagnostics is to test for illnesses, track the condition of an illness, direct treatment plans, and improve preventive care. In-Vitro Diagnostics comprises molecular diagnostics, immunoassays, clinical chemistry, hematology testing, and point-of-care diagnostics. IVD technology is crucial in detecting infectious diseases, cancer, diabetes, heart diseases, and genetic diseases.

In-Vitro Diagnostics is highly popular in Europe owing to its high demand in healthcare institutions in Europe due to several factors. Firstly, Europe has efficient healthcare infrastructure and stringent healthcare regulations that facilitate innovation in the IVD industry. Secondly, the population in Europe is aging rapidly; therefore, there is an increase in demand for IVD to diagnose illnesses among older populations. Thirdly, there is an increase in chronic illness cases in Europe, thus increasing the demand for IVDs. Fourthly, there is the expansion of molecular diagnostics in Europe, making home-based testing easier.

Top 10 European Countries by Chronic Disease Cases in 2025

Sources: OECD Health Statistics, European Commission Public Health Data, World Health Organization Europe Health Information Gateway

Company launches IVD product in Europe

• bioMérieux SA – Launched advanced BIOFIRE infectious disease diagnostic solutions and equine respiratory disease testing platforms in 2025.
• QIAGEN – Received CE-IVDR certification for the complete QIAstat-Dx syndromic testing portfolio, including an expanded meningitis/encephalitis panel in 2025.
• Roche Diagnostics – Expanded point-of-care diagnostics portfolio through the LumiraDx system rollout in Germany during 2025.
• Siemens Healthineers – Advanced digital pathology and AI-integrated diagnostic workflow solutions in European hospitals during 2025.
• Inbiome – Introduced an IVDR-certified rapid bacterial identification platform capable of identifying pathogens within five hours across EU hospitals.
• QIAGEN – Announced phased launches of QIAsymphony Connect and new laboratory automation sample preparation instruments in 2025.
• bioMérieux SA – Continued expansion of the BIOFIRE SPOTFIRE respiratory testing system for decentralized diagnostics and point-of-care applications.
• Roche Diagnostics – Expanded cobas molecular diagnostics and near-patient care testing solutions across European healthcare markets.
• Siemens Healthineers – Strengthened Atellica high-throughput immunoassay and laboratory automation solutions in Europe during 2025.
• Numares Health AG – Expanded the AXINON® automated IVD diagnostics platform for chronic disease and cancer detection applications.

Growth Drivers in the Europe In-Vitro Diagnostics (IVD) Market

Aging Population and Rising Burden of Chronic Diseases

According to calculations made by Eurostat, the proportion of people aged 65 or above in the overall European Union population will increase from 21.1 percent (94.3 million) in the year 2022 to 32.5 percent (136.1 million) by the year 2100. The continent of Europe is undergoing drastic changes in its demographics due to the rapid growth of the elderly population, which leads to an escalation in cases of chronic illnesses like diabetes, cardiovascular conditions, cancers, and kidney problems. Elderly patients need regular health checks and diagnostic tests, hence there is a growing demand for IVD devices in Europe. Healthcare professionals emphasize preventive medicine and the early diagnosis of diseases because they want to decrease the expenses related to their prolonged treatment. As life expectancy increases, diagnostic tests such as blood tests, biomarker screening, and chronic disease monitoring become important parts of any health care program. Based on the projections of Eurostat, there will be a significant rise in the percentage of people aged 65 years and older among the total population of the EU. As a result of the demographic trend of aging, there is likely to be a consistent need for diagnostic testing methods that are reliable, fast, and accurate.

Advancements in Diagnostic Technologies and Digital Healthcare

The continuous innovations in diagnostic technologies are having a huge impact on the transformation of the European In-Vitro Diagnostics market. New technologies like automation, Artificial Intelligence (AI), molecular diagnostics, and digital healthcare platforms have been enhancing the efficiency and precision of diagnostic testing procedures. The use of sophisticated and efficient equipment in European healthcare centers is aimed at improving diagnostic procedures to enhance patient care and experience. Technologies like Next-Generation Sequencing (NGS) and high throughput analyzers together with AI-driven diagnostics play a crucial role in the adoption of personalized medicine, which helps clinicians provide accurate diagnoses for effective patient management. Besides that, the emergence of new diagnostic methods based on miniaturization and laboratory automation enhances the efficiency and accuracy of workflows, lowering the risk of human errors. Moreover, the development of point-of-care testing and home diagnosis options increases the ease of access to diagnostics tests in Europe. On February 17th, 2023, bioMérieux SA launched the MONKEYPOX R-GENE PCR kit for qualitative virus detection in Research Use Only markets.

Strong Government Support and Advanced Healthcare Infrastructure

In Europe, highly advanced healthcare delivery systems coupled with an enabling regulatory framework are fostering the use of sophisticated diagnostic technologies in both the public and private sectors of healthcare. The government's emphasis on preventive medicine, disease surveillance, and early disease detection has continued to generate demand for In-Vitro Diagnostic medical devices within the country. Screening programs against cancer, infectious diseases, and other chronic illnesses have made diagnostics increasingly more crucial in the healthcare systems in Europe. Moreover, the implementation of favorable reimbursement structures in several EU nations has improved access to diagnostic procedures. In addition, regulatory authorities in Europe have encouraged innovation through the promotion of quality standards and research partnerships between healthcare organizations and In Vitro Diagnostic medical companies. Public investments in laboratory and healthcare information technology infrastructure are ensuring that Europe remains one of the most attractive markets for diagnostic technologies. In December 2022, the European Investment Bank signed a quasi-equity financing deal of €20 million with Numares Health AG, which specializes in an innovative AXINON® in-vitro diagnostic tool for chronic disease and cancer diagnostics.

Challenges in the Europe In-Vitro Diagnostics (IVD) Market

Complex Regulatory Environment

There are many hurdles in place when it comes to the European In-Vitro Diagnostics market owing to the implementation of the European Union In Vitro Diagnostic Regulation (IVDR). While the implementation of IVDR is aimed at ensuring safety of patients, enhancing product reliability and diagnostic accuracy through better clinical evidence and enhanced technical documentation, compliance issues remain a major obstacle. This has necessitated conformity assessments that involve a collaborative effort from notified bodies. The process has led to delays in terms of approvals as well as increased operational costs. The effects have been felt mostly by small and medium sized companies in the field due to limited funds and regulatory capabilities to cope with the complexities involved in the compliance process. Many companies have reported delays in the launch of their innovative diagnostics. Additionally, there has been some disruption of business in terms of the accessibility of products and the adoption of new technologies.

High Costs and Reimbursement Limitations

In spite of advanced health care infrastructures in Europe, the expensive nature of advanced In-Vitro Diagnostics systems continues to be a hindrance in terms of market acceptance. Modern diagnostic systems, molecular test kits, advanced automation systems, and personalized health care systems are quite expensive and thus require significant capital outlay by hospitals and medical laboratories. Small hospitals and medical labs within some European countries may lack the financial capacity to purchase such advanced technology. Furthermore, there is a large variation in the reimbursement systems used in different EU member countries. Some countries have excellent reimbursement schemes for their citizens, while others do not provide sufficient reimbursement cover for innovative diagnostic tests. This situation creates a price problem and uncertainty when implementing a common European strategy among multinational IVD corporations. Budget restrictions on health care provision and cost containment also play a role when making purchases of expensive diagnostic systems.

Europe ELISA & CLIA In-Vitro Diagnostics (IVD) Market

The ELISA (Enzyme-Linked Immunosorbent Assay) and CLIA (Chemiluminescence Immunoassay) sectors form critical parts of the European In-Vitro Diagnostics market. Both the ELISA and CLIA methods are extensively utilized for hormone testing, infectious pathogen diagnosis, autoimmune diseases, and disease biomarker identification of various diseases, including cancer, HIV, and hepatitis. High accuracy, precision, and sensitivity of these methods have made them highly beneficial for clinical diagnostics. Automation of ELISA and CLIA testing systems has led to increased laboratory efficiency and higher productivity levels among health care providers in Europe. A high prevalence of infectious and chronic diseases is continuously driving the uptake of advanced immunoassay methods. Moreover, Europe’s highly developed laboratory network and growing healthcare expenditure are contributing positively toward automation of in-vitro diagnostics. The ongoing innovation and increased attention towards early disease detection are anticipated to provide further impetus to the growth of the ELISA and CLIA IVD market in Europe.

Europe In-Vitro Diagnostics (IVD) Rapid Test Market

Rapid test kits represent a growing area of Europe's IVD market due to the ever-growing need for fast, easy-to-access, and affordable diagnostic tools. Rapid diagnostic tests are commonly applied for the detection of infectious diseases, pregnancy, blood glucose levels, and various medications. The growing consumer interest in decentralized health care services and self-diagnostic methods has positively impacted the growth and expansion of the rapid test segment within the European IVD market in both clinical and home care environments. The emergence and development of COVID-19 has resulted in the growing popularity and recognition of rapid diagnostic tests among medical specialists and regular patients. Rapid tests have proven their efficiency during the pandemic and, therefore, continue to be in high demand in other medical fields. Besides being a fast and reliable method of detecting diseases and conditions, rapid tests allow relieving the burden on hospital facilities and laboratories while ensuring that people living in distant regions have access to quality health care services.

Europe In-Vitro Diagnostics (IVD) Instruments Market

There is significant growth in the Europe IVD instruments market owing to rising demand for high-end diagnostic instruments in hospitals, clinical laboratories, and research centers. The Europe IVD instruments market comprises various diagnostic analyzers such as hematological analyzers, molecular diagnostic analyzers, clinical chemistry analyzers, and immunoanalyzers. Several health care organizations in Europe have been focusing on purchasing automated and high throughput diagnostic devices to ensure increased efficiency in operations. Integration of robotics, laboratory informatics systems, and artificial intelligence in diagnostic laboratories is further expected to increase the productivity and optimize laboratory processes. Various large hospitals and specialized laboratories across Europe remain focused on acquiring scalable and precision-based diagnostic analyzers to cope up with increasing testing volumes. Investments made by both public and private players in the health care sector towards modernization of laboratory infrastructure will further support market growth. Rising prevalence of chronic diseases and increasing demand for personalized medicines are among the key factors influencing the demand for high end diagnostic tools.

Europe In-Vitro Diagnostics (IVD) Infectious Disease Market

Infectious diseases represent a key part of Europe’s In-Vitro Diagnostics industry, due to increased focus on disease prevention, surveillance, and immediate response to disease outbreaks. Factors such as growing international travel, greater mobility, and the emergence of new threats associated with infectious diseases will contribute to higher demand for diagnostic tests in Europe. Tests used for the detection of influenza, HIV, hepatitis, tuberculosis, coronavirus, and other respiratory infections are currently in widespread use in Europe’s hospitals, laboratories, and public health services. Molecular diagnostic tests and antigen tests are especially popular because of their ability to rapidly detect pathogens. European health authorities encourage investment into new diagnostics as part of their programs to prevent and monitor infectious diseases. Innovations in multiplex diagnostic platforms that test for more than one pathogen at a time are revolutionizing treatment decisions and improving patient outcomes. Higher emphasis on pandemics and early detection of diseases is likely to result in sustained growth of the infectious diseases IVD sector in Europe.

Europe In-Vitro Diagnostics (IVD) Clinical Chemistry Market

The clinical chemistry sector represents an integral part of the European In-Vitro Diagnostic market and is indispensable for conducting routine clinical chemistry testing in hospitals and health care establishments. The clinical chemistry diagnostics comprise of metabolic tests, liver function tests, renal function tests, electrolyte measurements, and blood glucose measurement tests. The increasing prevalence of chronic diseases such as diabetes, heart ailments, and kidney ailments has raised the demand for clinical chemistry tests in the region. The introduction of automated laboratory equipment and systems has played a pivotal role in increasing the accuracy, efficiency, and productivity of laboratories. Healthcare organizations in Europe are highly dependent upon clinical chemistry diagnostic procedures for disease diagnosis, prevention, and treatment management. Further efforts to enhance testing sensitivity and quality control will fuel this market segment. In February 2023, bioMérieux SA was granted USFDA 510(k) clearance and CLIA approval for its BIOFIRE SPOTFIRE System and Respiratory Panel.

Europe In-Vitro Diagnostics (IVD) Laboratories Market

Labs form the base of the European In-Vitro Diagnostics market due to their role in conducting numerous tests in a variety of medical specialties. Modern technology-based diagnostics is being used more and more by both public and private labs in order to conduct tests faster, minimize errors and improve the speed with which patients can receive results. There has been an increase in the use of centralized high-throughput labs due to the requirement to perform extensive tests within large urban health care networks. The European In-Vitro Diagnostics market is benefitting from growing partnerships between IVD manufacturers, biotech organizations and universities working on advancing diagnostics technology. Governments continue to make significant investments into laboratory facilities, workforce development and digitization of healthcare services in order to advance Europe's diagnostics capabilities. Moreover, the increasing demand for precision medicine and diagnostics, testing for infections diseases and chronic diseases will further fuel the expansion of the lab sector within the region.

Germany In-Vitro Diagnostics (IVD) Market

Being at the forefront of European In-Vitro Diagnostic market is mainly attributed to the highly advanced infrastructure, medical research abilities and diagnostics lab availability that Germany possesses. Being a major center of diagnostic innovations with an extensive interaction among universities, biotechnological companies and health institutions, the country maintains its leadership in this field. Growing rates of chronic conditions together with the aging German population create huge demands for the high-quality solutions for diagnostics. Due to high importance of accuracy and precision in the German healthcare system, the use of such tests as molecular diagnostics, immunoassays, and automation of laboratory operations became very popular. Also, Germany puts considerable efforts into digitalization and modernization of its healthcare system. Besides, government support of medical research and technological development stimulates growth of the market. All in all, high attention paid to healthcare innovations and preventive care makes Germany one of the leading countries in the area.

France In-Vitro Diagnostics (IVD) Market

In Vitro Diagnostics Market in France has been consistently showing positive developments owing to the presence of efficient healthcare policies adopted by the government, national screening programs and increased focus on disease management, especially that related to infections. France has a robust healthcare system which facilitates widespread diagnostic tests in hospitals, laboratories and special health care centers. France is constantly seeing an increase in demand for molecular diagnostics in various sectors such as oncology, infectious diseases, and personalized medicine. Moreover, the use of automated and computerized tools in the work processes of various diagnostic laboratories has been increasing considerably. In addition, the aging demographic of the country and increasing incidences of chronic diseases have resulted in higher requirements of routine testing and continuous monitoring of patients. Developments in the healthcare sector in terms of biotechnology and investments in infrastructure are also positively contributing towards market growth in the country. Therefore, France's In Vitro Diagnostics Market is showing positive trends because of technology adoption and preventive healthcare.

United Kingdom In-Vitro Diagnostics (IVD) Market

The United Kingdom can be considered one of the most innovative and scientific In-Vitro Diagnostics markets in Europe, based on the NHS and the robustness of its biotech industry. After the COVID-19 outbreak, there was an emphasis on decentralized health care models, including point-of-care diagnostics and home health diagnostics. The rise in personalized medicine and genetics testing drives the adoption of molecular diagnostics and companion diagnostics technologies across the healthcare industry. The UK's advanced research and development capacity, strategic health care partnerships, and reimbursement policies are among the factors that support the ongoing development of the IVD industry in the country. At the same time, the regulatory changes after Brexit add an extra layer of complexity to the diagnostic industry. Until June 2023, devices with valid CE marks would comply with the UK regulations, while the significance of UKCA certification increased after this date. Despite this new regulatory framework, the United Kingdom remains an innovative and technologically advanced IVD market driven by research and innovation.

Netherlands In-Vitro Diagnostics (IVD) Market

The Netherlands possesses an extremely progressive and effective In-Vitro Diagnostics market that operates thanks to the advanced public healthcare system as well as the presence of numerous innovative technologies in diagnostics. The automated, high-throughput systems for diagnosing are widely used by laboratories to cope with the growing workload of tests while remaining cost-efficient and precise. In addition, such innovations as digital healthcare and at-home diagnostic tests are promoted in the Netherlands, which confirms its orientation towards patients and medical accessibility. Growing popularity of molecular diagnosis, rapid testing, and clinical chemistry products ensures further market growth. Government measures promoting innovation and digital healthcare are contributing to the development of diagnostic infrastructure in the Netherlands, which also takes part in various European healthcare research projects. In particular, the Netherlands maintains close cooperation between educational institutions, biotechnological firms, and IVD manufacturers, contributing to the development and improvement of new technologies. As a result, the country can be considered among the leaders in innovation within Europe's IVD market.

Europe In-Vitro Diagnostics (IVD) Market Segments

Test Types

• ELISA & CLIA
• PCR
• Rapid Test
• Fluorescence Immunoassays (FIA)
• In Situ Hybridization
• Transcription Mediated Amplification
• Sequencing
• Colorimetric Immunoassay
• Radioimmunoassay (RIA)
• Isothermal Nucleic Acid Amplification Technology
• Others

Product

• Services
• Instruments
• Reagents

Application

• Infectious Disease
• Diabetes
• Cardiology
• Oncology
• Nephrology
• Autoimmune Diseases
• Drug Testing
• Other Applications

Technology

• Immunoassay
• Clinical Chemistry
• Molecular Diagnostics/Genetics
• Hematology
• Microbiology
• Coagulation
• Others

End User

• Hospitals
• Laboratories
• Home Care
• Others

Countries

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

Companies have been covered from 5 viewpoints

• Overviews
• Key Person
• Recent Developments
• Product Portfolio    
• Revenue

Company Analysis

• Roche Diagnostics
• Abbott Diagnostics
• Siemens Healthineers
• Danaher Corporation
• Thermo Fisher Scientific
• Sysmex Corporation

Report Details: